Precision Medicine in Targeting ROS1- Rearranged Non-small Cell Lung Cancer

Globally, lung cancer is the leading cause of death from cancer among men and women. The overall 5-year survival rate of lung cancer is around 16-19%. The emergence of targeted therapy and immunotherapy have changed the treatment paradigm of advanced NSCLC. Figure 1: Frequency of molecular subtypes of non-small cell lung cancer of adenocarcinoma histology with a focus on ROS1 rearrangement. Citation: Ahmed Y, Dennehy C, Jordan E, Calvert P (2019) Precision Medicine in Targeting ROS1Rearranged Non-small Cell Lung Cancer. J Cancer Sci Ther 11: 224-227. J Cancer Sci Ther, an open access journal ISSN: 1948-5956 Volume 11(7) 224-227 (2019) 225 EGFR mutations, and BRAFmutations in patients with advanced nonsquamous NSCLC or NSCLC not otherwise specified (NOS) [1]. Current Testing Methods The most common ROS1 fusion partners are CD74, SLC34A2, CCDC6, and FIG [1]. Currently, no US Food and Drug Administration (FDA)-approved companion diagnostic tests exist for ROS1-rearranged NSCLC [6]. Methods to detect ROS1 rearrangements include FISH, IHC, RT-PCR, and NGS [4,6].